Ageless Pep Academy Clinical Education · Licensed Prescribers

IGF-1 LR3

IGF-1 LR3

⚠️ Structural Separation Notice

The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.

Quick Facts

  • Full Name: Long R3 Insulin-Like Growth Factor-1
  • Aliases: IGF-1 LR3, Long-R3-IGF-I
  • Category: Muscle Building / Fat Loss / Recovery
  • Molecular Weight: ~9117 Da (83-AA analogue)
  • Administration: Subcutaneous (post-workout preferred)
  • Typical Dose: 20–50 mcg/day SubQ post-workout
  • Half-Life: ~20–30 hours (vs ~12–15 min for native IGF-1, due to reduced IGFBP binding)
  • Cycling: 4–6 week cycles; extended use risks hypoglycemia and receptor desensitization
  • Status: Research Only — higher risk profile than most peptides

What It Does

IGF-1 LR3 is a recombinant analogue of IGF-1 with an N-terminal extension (Arg3) and substitution that dramatically reduces its binding to IGF Binding Proteins (IGFBPs), extending its half-life 30-fold. This makes it significantly more potent and longer-acting than native IGF-1 — activating the IGF-1R across muscle, fat, and connective tissue simultaneously. It drives satellite cell activation, protein synthesis, and lipolysis, but with a significant hypoglycemia risk.

Mechanism of Action

  1. IGF-1R agonism: Binds IGF-1 receptor → PI3K/Akt/mTOR → protein synthesis, satellite cell activation
  2. Reduced IGFBP binding: Arg3 substitution + N-terminal extension → 30x longer half-life vs native IGF-1
  3. Satellite cell activation: Stimulates muscle stem cell (satellite cell) proliferation and differentiation → muscle hyperplasia
  4. Protein synthesis: Upregulates mTORC1, p70S6K, and 4E-BP1 → enhanced muscle protein synthesis
  5. Lipolysis: IGF-1R activation in adipose tissue → fat oxidation
  6. Insulin-like hypoglycemic effect: Activates IR (insulin receptor) at high doses → glucose uptake → hypoglycemia risk

Ageless Peps Products

  • AP-IGF1LR3-Vial — IGF-1 LR3 Vial, $160, retail (draft status)

Dosing Protocols

Standard Protocol

  • Dose: 20–50 mcg SubQ
  • Timing: Post-workout (30–60 min after training; local injection near worked muscle for regional hypertrophy)
  • Frequency: Daily or every other day
  • Cycling: 4–6 weeks on; 6–8 weeks off (receptor desensitization prevention)

Conservative Start

  • Dose: 20 mcg/day to assess glucose response
  • Monitoring: Blood glucose monitoring recommended, especially initially

Stacks Well With

  • CJC-1295 NO DAC + Ipamorelin – GH axis amplification of IGF-1 effects
  • PEG-MGF – satellite cell activation + IGF-1 LR3 muscle growth stack
  • BPC-157 – recovery + injury protection during anabolic cycle

Use Cases

  • Muscle Building / Muscle hyperplasia
  • Fat Loss / Body recomposition
  • Recovery from injury or intense training
  • Sarcopenia (investigational)

Contraindications & Safety

  • Active malignancy (absolute) — IGF-1R drives tumor proliferation; significant risk
  • Diabetic retinopathy — IGF-1 worsens retinal neovascularization
  • Hypoglycemia risk — must have fast-acting carbohydrates available; monitor blood glucose
  • Acromegaly features — jaw/hand/foot growth possible with chronic high-dose use
  • Higher risk profile than other peptides in this database — use with caution
  • Common: Hypoglycemia, injection site reactions, headache, water retention

Storage

  • Lyophilized: -20°C for 1–2 years; avoid freeze-thaw cycles
  • Reconstituted: 2–8°C; use within 2–3 weeks; use acetic acid for reconstitution (NOT bacteriostatic water)

PubMed Research

Studies

Sources

#muscle-building #fat-loss #recovery #igf1 #peptide